mAbs recognizing TCR V gene products have helped to define a unique group of potent T cell activators termed superantigens (1). Recognized superantigens include murine selfantigens (2, 3) and a group ofmicrobial toxins, the staphylococcal enterotoxins (SE) (1), and a soluble product ofMycoplasma arthritidis mitogen (MAM) (4). Superantigens share a number of intriguing characteristics. For example, superantigen recognition is almost entirely a function of TCR V a gene usage (1, 2).
In addition, superantigens bind selectively and with high affinity to MHC class II molecules (6) . In the absence of antigen processing and in an MHC-nonrestricted manner, superantigen-MHC class II complexes on the APC surface trigger the proliferation of T cells expressing the relevant TCR V gene product (5) . Finally, the microbial toxins that function as superantigens are among the most potent mitogens known.
The dual affinity of superantigens for MHC class II and TCR V gene products suggests that this class of antigen could promote a form of abnormal Th-B cell collaboration analogous to that observed during graft-vs .-host disease (GVHD). In GVHD, adoptive transfer of donor Th cells, specific for recipient MHC class II antigens, triggers polyclonal B cell activation . In selected strains of nonautoimmune prone mice, GVHD is characterized by an autoimmune diathesis remarkably similar to SLE (6) . It has been suggested that in GVHD, the presence of both self antigens and donor-derived Th cells, reactive against recipient MHC class II antigens, provides a combination of stimuli that selectively drives autoreactive B cell differentiation (6) .
The experiments described below were designed to determine if a superantigen bridge between Th cells and B cells would result in an analogous form ofpolyclonal human B cell activation . MAM was selected for study in view ofthe chronic inflammatory arthritis that M. arthritidis induces in rodents (7) , and scattered reports of M. arthritidis cultured from the bone marrow of patients with SLE (8).
Results and Discussion After 4 d of in vitro sensitization with the partially purified superantigen, MAMresponsive T cell blasts were isolated from the nonresponsive, resting T cell population by discontinuous Percoll gradient centrifugation . Table I demonstrates that the T cell blast population was enriched, and the resting T cell population depleted, of MAM-reactive T cells, as determined by proliferation . The T cell blasts respond to MAM with a vigorous and accelerated (day 2) proliferative response compared with fresh PBL. In contrast, the resting T cell population proliferates to control stimuli, either PHA or a distinct bacterial superantigen, SEB, but not to MAM .
Phenotypic analysis of the MAM blast population revealed approximately equal distribution of CD4 + and CD8' T cells. To maximize the likelihood of detecting MAM-dependent Th cell activity, the CD4' helper/inducer subset of MAMreactive T cell blasts was isolated by immune rosette depletion of CD8' cells. This procedure yielded a T cell population that was >98% CD4', and maintained an accelerated proliferative response to MAM in the presence ofautologous, allogeneic, or xenogeneic APC (Table I, Exp . 3).
MAM-reactive CD4' T cell blasts were assayed for helper activity. As shown ( Fig.  1 A) , little IgM is produced in B cell cultures supplemented with MAM alone or MAM plus unselected autologous T cells. In contrast, a striking IgM response is induced in cultures containing both MAM-reactive CD4' T cell blasts and MAM . This B cell response is MAM dependent, but not MHC restricted. Thus, B cells derived from all donors tested, regardless of HLA haplotype, are activated by CD4' MAM-reactive T cells in the presence of MAM (data not shown). In preliminary studies, we noted that MAM-reactive TCL, comprised of both CD4' and CD8+ cells, often trigger little Ig production. This suggested restriction of helper activity to the CD4' MAM-reactive T cell subset . The experiment presented in Fig. 1 B confirms this impression. While both CD4' and CD8+ MAMreactive T cell blasts proliferate in response to MAM, only CD4 } cells provide MAM-dependent help for B cell activation, as assessed by Ig production .
In related studies, we examined TCR V-0 gene family usage by MAM-reactive human T cells. ' We noted a strong negative correlation between MAM-reactive T cells and T cells expressing TCR V-0 5 gene products recognized by mAb C37 (9), and V a 6.7 recognized by mAb OT145 (10) . To prove that MAM-dependent B cell activation requires superantigen-specific Th cells, CD4' TCL were obtained from cultures of PBL stimulated with either MAM or the mAb C37. As expected, MAMreactive TCL were depleted of C37-expressing cells, while the C37-stimulated culture contained >95 To C37+ T cells. In functional assays (Fig. 2 A) , the CD4+ , C37 + TCL provides help for B cell differentiation in the presence ofPWM. However, only the MAM-reactive CD4`TCL drives B cell differentiation in the presence of MAM.
Antibody production by resting B cells requires direct cognate cell-cell interaction with antigen-specific Th cells, as well as the action of lymphokines (11) tion in this model is also dependent on cognate Th-B cell interaction (12) . To postulate a role for superantigens in the in vivo activation ofnormally quiescent, autoreactive B cells, it is crucial to demonstrate that superantigens can promote a productive Th-resting B cell interaction. To address this question, high density resting tonsillar B cells were incubated with MAM or medium alone for 1 h at 37°C, then washed extensively. These B cell populations were subsequently cultured with MAM-specific Th cells and polyclonal IgM secretion assayed by ELISA. As shown in Fig. 2 MAM-reactive or C37' TCL were generated as described above. Aliquots of these TCL were assayed for polyclonal B cell help as described in Fig. 1 . At the time of assay, the MAMreactive line was >98% CD4' and <0 .1 C37' ; and the C37' -line was >98% CD4' and The observation that superantigens activate subsets of T cells based on TCR V gene usage has led to speculation that these substances may induce organ-specific autoimmunity by activating normally quiescent autoreactive T cells (1) . In addition, however, the affinity of superantigens for MHC class II molecules and their recognition by T cells in the absence of processing suggested to us that bacterial superantigens may also perturb the immune system in a manner analogous to that seen in GVHD. For example, any B cell, regardless of its specificity for antigen, may bind a superantigen and be rendered a target ofcognate T cell help by superantigenspecific Th cells. The studies reported here support this hypothesis. While this manuscript was in preparation, Mourad et al. reported similar results using the Staphylococcal toxic shock syndrome toxin (13) . Together, these two reports suggest that productive Th-B cell bridging may be a common feature of microbial superantigens . 
